NASDAQ:NVCRNovocure Stock Price, Forecast & News

Novocure's stock was trading at $67.38 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, NVCR shares have increased by 17.2% and is now trading at $78.99.
View which stocks have been most impacted by Coronavirus.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novocure in the last year. There are currently 1 sell rating, 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Novocure.

Novocure is scheduled to release its next quarterly earnings announcement on Thursday, October 29th 2020.
View our earnings forecast for Novocure.

Novocure Ltd (NASDAQ:NVCR) issued its earnings results on Thursday, July, 30th. The medical equipment provider reported $0.02 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.01 by $0.01. The medical equipment provider had revenue of $115.90 million for the quarter, compared to the consensus estimate of $105.96 million. Novocure had a return on equity of 5.14% and a net margin of 2.88%. The company's quarterly revenue was up 33.7% compared to the same quarter last year. During the same quarter last year, the business earned ($0.01) EPS.
View Novocure's earnings history.

8 equities research analysts have issued 12-month price objectives for Novocure's shares. Their forecasts range from $58.00 to $90.00. On average, they anticipate Novocure's stock price to reach $79.75 in the next year. This suggests a possible upside of 1.0% from the stock's current price.
View analysts' price targets for Novocure.

Media headlines about NVCR stock have trended positive this week, according to InfoTrie. The research firm identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Novocure earned a daily sentiment score of 2.1 on InfoTrie's scale. They also gave media headlines about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days.
View the latest news about Novocure.

Novocure saw a decline in short interest in July. As of July 31st, there was short interest totaling 3,150,000 shares, a decline of 6.8% from the July 15th total of 3,380,000 shares. Based on an average daily volume of 1,010,000 shares, the short-interest ratio is currently 3.1 days. Currently, 3.8% of the company's shares are short sold.
View Novocure's Current Options Chain.

Some companies that are related to Novocure include FRESENIUS SE &/S (FSNUY), ResMed (RMD), Teleflex (TFX), Insulet (PODD), ABIOMED (ABMD), Penumbra (PEN), Tandem Diabetes Care (TNDM), Hill-Rom (HRC), Globus Medical (GMED), Irhythm Technologies (IRTC), Nevro (NVRO), Integra Lifesciences (IART), Haemonetics (HAE), ICU Medical (ICUI) and Inovio Pharmaceuticals (INO).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Novocure investors own include Chembio Diagnostics (CEMI), Prospect Capital (PSEC), Calumet Specialty Products Partners, L.P (CLMT), Two Harbors Investment (TWO), Blackrock Capital Investment (BKCC), Viper Energy Partners (VNOM), Summit Midstream Partners (SMLP), NVIDIA (NVDA), Washington Prime Group (WPG) and Roper Technologies (ROP).

Novocure trades on the NASDAQ under the ticker symbol "NVCR."

Novocure's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Rhenman & Partners Asset Management AB (0.37%), C WorldWide Group Holding A S (0.34%), New York State Common Retirement Fund (0.26%), Redwood Investments LLC (0.19%), Peregrine Capital Management LLC (0.19%) and Swiss National Bank (0.19%). Company insiders that own Novocure stock include Asaf Danziger, Charles G Phillips III, Ely Benaim, Gabriel Leung, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Wilhelmus Cm Groenhuysen, William F Doyle and Yoram Palti.
View institutional ownership trends for Novocure.

NVCR stock was sold by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, First Trust Advisors LP, SG Americas Securities LLC, Raymond James Financial Services Advisors Inc., Russell Investments Group Ltd., Chartwell Investment Partners LLC, ProShare Advisors LLC, and Essex Financial Services Inc.. Company insiders that have sold Novocure company stock in the last year include Asaf Danziger, Charles G Phillips III, Ely Benaim, Gabriel Leung, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Wilhelmus Cm Groenhuysen, and William F Doyle.
View insider buying and selling activity for Novocure.

NVCR stock was bought by a variety of institutional investors in the last quarter, including C WorldWide Group Holding A S, Kornitzer Capital Management Inc. KS, New York State Common Retirement Fund, Peregrine Capital Management LLC, Swiss National Bank, Northstar Asset Management LLC, Rhenman & Partners Asset Management AB, and Principal Financial Group Inc..
View insider buying and selling activity for Novocure.

Shares of NVCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NVCR stock can currently be purchased for approximately $78.99.

Novocure has a market capitalization of $7.99 billion and generates $351.32 million in revenue each year. The medical equipment provider earns $-7,230,000.00 in net income (profit) each year or ($0.07) on an earnings per share basis.

The official website for Novocure is www.novocure.com.

Novocure's mailing address is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. The medical equipment provider can be reached via phone at 44-0-15-3475-6700 or via email at [email protected]